FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvaoriii igtori,	D.O.	20010

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Schuchart Aaron  (Last) (First) (Middle)  4200 MARATHON BLVD						2. Issuer Name and Ticker or Trading Symbol LUMOS PHARMA, INC. [ (LUMO) ]  3. Date of Earliest Transaction (Month/Day/Year) 02/01/2023									Relationship of Reporting Person(s) to Issuer heck all applicable)  Director 10% Owner  X Officer (give title Other (specify below)  Chief Business Officer				
(Street) AUSTIN (City)	T)		78756 (Zip)		4. l	f Ame	ndment, [	Date o	of Original	Filed	(Month/Da	Line	ndividual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person Form filed by More than One Reporting Person						
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					saction	2A. Deemed Execution Date,								A) or	5. Amou Securitie	nt of	Form	n: Direct	7. Nature of Indirect
					/Day/Ye	Day/Year) if any (Month/D		ıy/Yeaı	Code (8)	v	5)	(A)	) or	Price	Benefici Owned F Reported Transact (Instr. 3	Following (I) ed etion(s)		str. 4)	Beneficial Ownership (Instr. 4)
Common Stock 02/0					1/202	/2023		A		1,000	(1)	A	\$3.52	2 5,483	5(2)(3)(4)		D		
Common Stock 02/01/				1/202	/2023		F		104(5	5)	D	\$3.52	5,38	5,381(2)(3)(4)		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transactio Code (Insi				6. Date Exercisal Expiration Date (Month/Day/Year		•	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ow For Oir Or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	or No of	umber					
Stock Option (Right to Buy)	\$3.52	02/01/2023			A		12,000		(6)(7)		(8)	Commo		2,000	\$0	12,000	0	D	

## **Explanation of Responses:**

- 1. Represents shares issued as restricted stock units ("RSUs") under the Issuer's 2009 Equity Incentive Plan, as amended, (the "Plan") that were received as an award, for no consideration. The RSUs vest in a series of four successive annual installments beginning on February 1, 2024, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
- 2. Includes 348 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of two successive annual installments with the next installment occurring on February 1, 2024, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan
- 3. Includes 750 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of three successive annual installments with the next installment occurring on February 1, 2024, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan
- 4. Includes 500 shares acquired under the Lumos Pharma, Inc. 2010 Employee Stock Purchase Plan on December 31, 2022.
- 5. Represents shares of Common Stock withheld by the Issuer in satisfaction of its tax withholding obligation with respect to the vesting of 424 previously reported restricted stock units ("RSUs") granted to the Reporting Person.

6. Grant to the Reporting Person of a stock option under the Plan. 50% of the option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on March 1, 2023, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. The option expires ten years after the Date of Grant.

- 7. The remaining 50% of the stock options vest and become exercisable in 3 substantially equal tranches on the first of the month following an increase of closing stock price, as defined as the closing stock price on Nasdaq Stock Market by at least 50%, 100% and 150%, respectively, above the closing stock on December 31, 2022, when measured over 30 consecutive calendar days, provided such increase occurs within two years of the Date of Grant, otherwise such options shall be cancelled.
- 8. Unless otherwise disclosed, the option expires ten years after the date of grant.

## Remarks:

/s/ Ryan Trytten, attorney-infact \*\* Signature of Reporting Person

02/03/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.